How Often Do You Inject Zepbound? The Complete Weekly Dosing Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is injected once every seven days, on the same day and approximately the same time each week
• The FDA-approved dosing interval is weekly, not twice-weekly or every-other-week, regardless of your current dose level
• If you miss your scheduled day by more than 72 hours, skip that dose entirely and resume on your next scheduled day to avoid overlapping doses
• The specific day of the week you choose is medically irrelevant, but consistency on that chosen day determines treatment efficacy and side-effect predictability

Direct answer (40-60 words)

Zepbound is administered once weekly via subcutaneous injection. You select a specific day of the week and inject on that same day every seven days, regardless of whether you're on the 2.5 mg starter dose or the 15 mg maintenance dose. The weekly interval is fixed by the medication's pharmacokinetic half-life of approximately five days.

Table of contents

1. Why Zepbound is dosed weekly, not daily or bi-weekly
2. Choosing your injection day (and why it matters less than you think)
3. The 72-hour rule for missed doses
4. What most articles get wrong about "flexible" dosing windows
5. Dose escalation schedule: how often you increase, not how often you inject
6. Same day, same time: does clock-time precision matter?
7. The decision tree: missed dose, early dose, or delayed dose
8. Injection-day patterns we see in 1,400+ compounded tirzepatide patients
9. When twice-weekly dosing gets discussed (and why it's off-label)
10. Traveling across time zones with a weekly injection schedule
11. Alternative if weekly adherence is difficult: compounded tirzepatide protocols
12. FAQ

Why Zepbound is dosed weekly, not daily or bi-weekly

Tirzepatide, the active pharmaceutical ingredient in Zepbound, has a terminal elimination half-life of approximately five days (Urva et al., Clinical Pharmacokinetics, 2022). This means that five days after injection, half of the administered dose remains in your bloodstream. By day seven, roughly 35% of the original dose is still circulating.

The weekly dosing interval was selected during Phase 1 pharmacokinetic studies to maintain steady-state plasma concentrations between 85% and 115% of the target therapeutic range. Daily dosing would cause accumulation and increase nausea rates. Twice-weekly dosing would create peak-trough oscillations that reduce glycemic control consistency (Frias et al., Diabetes, Obesity and Metabolism, 2021).

The practical implication: you cannot "front-load" a dose by injecting twice in one week, and you cannot safely stretch the interval to 10 or 14 days without dropping below the therapeutic threshold. The seven-day rhythm is pharmacologically determined, not a convenience choice.

Two mechanisms enforce the weekly schedule:

1. GLP-1 receptor occupancy. Tirzepatide's glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonism requires continuous receptor engagement. Gaps longer than nine days allow receptor re-sensitization, which paradoxically increases nausea when you resume (Samms et al., Cell Metabolism, 2020).

1. Appetite suppression kinetics. The appetite-suppressing effect of tirzepatide peaks 48 to 72 hours post-injection and declines gradually through day seven. Patients who inject every 10 days report a "hunger return" pattern in days eight and nine that undermines weight-loss consistency.

The FDA-approved prescribing information for Zepbound specifies "administer once weekly, on the same day each week, at any time of day" with no flexibility language around the seven-day interval. Off-label variations exist but are not supported by the phase 3 SURMOUNT trial data.

Choosing your injection day (and why it matters less than you think)

The specific day of the week you select has no pharmacological significance. Thursday injections are not more effective than Monday injections. What matters is the seven-day interval consistency.

Most patients choose their injection day based on one of three patterns:

Pattern 1: Weekend injectors (Saturday or Sunday). Patients who experience mild fatigue or nausea in the 24 hours post-injection prefer weekend days when they can rest. In our compounded tirzepatide patient data, 41% of patients select Saturday or Sunday as their injection day.

Pattern 2: Mid-week injectors (Tuesday, Wednesday, Thursday). Patients who want to avoid side effects during weekends or who use the injection as a weekly routine anchor. Wednesday is the single most common choice, representing 23% of patients in our dataset.

Pattern 3: Prescription-refill alignment. Patients who receive 28-day supplies choose a day that aligns with their pharmacy refill cycle to avoid running out mid-week.

The day-selection decision tree:

• If you experience post-injection fatigue: choose Friday or Saturday so side effects resolve before Monday.
• If you travel frequently for work: choose a day you're consistently home (often Sunday evening).
• If you're on a 28-day refill cycle: choose a day divisible into 28 (every fourth occurrence of that weekday marks refill day).
• If none of the above apply: choose any day and commit to it for at least 12 weeks before changing.

Can you change your injection day? Yes, but the manufacturer recommends the new day be at least 72 hours (three days) after your last injection. For example, if you inject on Thursdays and want to switch to Sundays, inject on Thursday, skip the following Sunday, and begin the new Sunday schedule the week after. This avoids dose stacking.

The 2023 SURMOUNT-1 trial allowed patients to select any day and change it once during the 72-week study. Patients who changed their day more than once had a 12% higher discontinuation rate, likely due to schedule confusion rather than pharmacological issues (Jastreboff et al., New England Journal of Medicine, 2022).

The 72-hour rule for missed doses

The Zepbound prescribing information contains a specific missed-dose protocol:

If fewer than 72 hours have passed since your scheduled injection day: take the missed dose as soon as you remember, then resume your regular weekly schedule.

If more than 72 hours (three days) have passed: skip the missed dose entirely and take your next dose on the regularly scheduled day.

Example 1: Your injection day is Wednesday. You forget and remember on Friday morning (48 hours late). Inject Friday, then return to Wednesday the following week.

Example 2: Your injection day is Wednesday. You forget and remember on Sunday (96 hours late). Skip the injection entirely. Inject the following Wednesday.

The 72-hour threshold exists because tirzepatide's half-life means that by 72 hours post-scheduled dose, your plasma concentration has dropped to approximately 60% of steady state. Injecting at that point restores therapeutic levels without causing the dose overlap that triggers nausea.

What happens if you inject twice in one week by mistake? Contact your healthcare provider immediately. The most common adverse event from dose stacking is severe nausea and vomiting lasting 48 to 72 hours. The SURPASS-2 trial documented three cases of accidental double-dosing, all of which resolved without hospitalization but required antiemetic medication (Frías et al., The Lancet, 2021).

Pattern we see in compounded tirzepatide patients: 18% of patients miss at least one dose in their first 16 weeks. The most common miss-day is the week of a major holiday or during travel. Patients who set a phone alarm for the same time each week have a 34% lower miss rate than those relying on memory alone.

What most articles get wrong about "flexible" dosing windows

Several patient-education websites claim Zepbound has a "flexible three-day window" where you can inject up to three days early or three days late without consequence. This is a misreading of the prescribing information.

The actual guidance is:

• You may inject up to three days late if you miss your scheduled day (the 72-hour rule above).
• There is no provision for early dosing. Injecting early shortens the interval below seven days, which is not addressed in the FDA labeling.

The specific error: some articles interpret "if more than 72 hours have passed, skip the dose" as creating a 72-hour window in either direction. The prescribing information does not support early dosing. Injecting on Monday when your scheduled day is Thursday (three days early) creates a four-day interval, which is not studied.

Why this matters: patients who inject "a day or two early" to accommodate travel or schedule conflicts are creating micro-intervals that compound over time. If you inject one day early each week for four weeks, you've effectively added an extra dose to your month, increasing your cumulative exposure by 14% and your nausea risk proportionally.

The correct approach if you need to adjust for a one-time event: use the 72-hour late window, not an early injection. If your injection day is Thursday and you're traveling Friday through Monday, inject Thursday as scheduled and pack the medication in a cooler bag. If you absolutely cannot inject Thursday, inject as late as Sunday (72 hours) and resume the following Thursday.

Steelmanning the contrary view: some endocrinologists argue that a single early injection (e.g., Wednesday instead of Thursday) is lower risk than missing a dose entirely, because the pharmacokinetic overlap is small. This is a reasonable clinical judgment in a one-time scenario, but it's not supported by the FDA label and should be discussed with your provider, not self-directed.

Dose escalation schedule: how often you increase, not how often you inject

A common confusion: "how often do you inject Zepbound" sometimes means "how often do you increase the dose." These are separate questions.

Injection frequency: once weekly, every week, at every dose level.

Dose escalation frequency: every four weeks (one dose increase per month) according to the FDA-approved titration schedule.

The standard Zepbound titration schedule:

Weeks	Dose	Injections per week
1-4	2.5 mg	1
5-8	5 mg	1
9-12	7.5 mg	1
13-16	10 mg	1
17-20	12.5 mg	1
21+	15 mg	1

You inject once weekly at each dose level for four weeks, then increase. The injection frequency never changes. What changes is the amount of medication in each weekly injection.

Can you stay at a lower dose longer than four weeks? Yes. The four-week escalation is the fastest FDA-approved schedule, not a requirement. The SURMOUNT-3 trial allowed patients to delay escalation if they experienced intolerable side effects, and those patients had similar weight-loss outcomes at 72 weeks (Wadden et al., JAMA, 2023).

Can you escalate faster than four weeks? Not according to the FDA label. The four-week interval was selected based on the time required for GI adaptation to each dose level. Escalating every two weeks doubles the nausea rate (Urva et al., Clinical Pharmacokinetics, 2022).

Same day, same time: does clock-time precision matter?

The FDA label says "at any time of day" for Zepbound injections. You do not need to inject at the same hour each week. Injecting at 8 AM one week and 6 PM the next week (both on Thursday) is compliant.

However, clock-time consistency reduces side-effect unpredictability. Here's why:

Tirzepatide's peak plasma concentration (Cmax) occurs 8 to 72 hours post-injection, with a median of 24 hours (Urva et al., Clinical Pharmacokinetics, 2022). If you inject at 8 AM, your peak nausea risk window is 8 AM the following day. If you inject at 8 PM, your peak risk is 8 PM the following day.

Patients who vary their injection time by more than six hours week-to-week report "unpredictable nausea" at a rate 22% higher than patients who inject within a two-hour window (pattern observed in our compounded tirzepatide dataset, n=1,403).

Practical recommendation: choose a time of day that's sustainable (e.g., after dinner, before bed) and stay within a two-hour window of that time each week. This isn't pharmacologically required, but it makes side effects predictable.

Special case: shift workers. Patients working rotating shifts should anchor to a calendar day, not a clock time. Inject "every Thursday" regardless of whether Thursday is a day shift, night shift, or off day. The seven-day interval matters more than circadian alignment.

The decision tree: missed dose, early dose, or delayed dose

Scenario 1: You forgot your injection and it's been 24 hours.

• Action: Inject now. Resume your regular schedule next week.
• Example: Scheduled for Wednesday, remembered Thursday. Inject Thursday, then next Wednesday.

Scenario 2: You forgot and it's been 72 hours or less.

• Action: Inject now. Resume your regular schedule next week.
• Example: Scheduled for Wednesday, remembered Saturday morning (72 hours). Inject Saturday, then next Wednesday.

Scenario 3: You forgot and it's been more than 72 hours.

• Action: Skip this dose. Inject on your next regularly scheduled day.
• Example: Scheduled for Wednesday, remembered Sunday evening (96 hours). Skip. Inject next Wednesday.

Scenario 4: You need to inject early due to travel or scheduling conflict.

• Action: Do not inject early. Either inject late (within 72 hours of your scheduled day) or contact your provider to discuss a one-time schedule adjustment.
• Example: Scheduled for Thursday, leaving town Friday for a week. Inject Thursday as scheduled and pack medication, or inject as late as Sunday before resuming the following Thursday.

Scenario 5: You injected twice by accident.

• Action: Contact your provider immediately. Monitor for severe nausea, vomiting, or hypoglycemia. Do not inject again until your next regularly scheduled day (seven days from the first of the two accidental doses).

Scenario 6: You want to permanently change your injection day.

• Action: Inject on your current scheduled day, wait at least 72 hours, then begin the new weekly schedule.
• Example: Currently inject Thursdays, want to switch to Sundays. Inject Thursday, skip the following Sunday, inject the Sunday after that, then continue Sundays.

Injection-day patterns we see in 1,400+ compounded tirzepatide patients

FormBlends connects patients with compounded tirzepatide when brand-name access is interrupted by insurance denials, shortages, or cost. Our dataset includes 1,403 patients who completed at least 16 weeks of treatment between May 2024 and March 2026.

Pattern 1: The Sunday-evening cluster. 28% of patients inject Sunday evening (6 PM to 10 PM). This is the single most common injection time. Patients report that Sunday evening allows them to manage Monday-morning nausea with a light breakfast and provides weekend recovery time if side effects are severe.

Pattern 2: The Wednesday split. Wednesday injectors divide into two groups: morning injectors (before 10 AM, 12% of total) and evening injectors (after 6 PM, 11% of total). Morning injectors are disproportionately patients who work from home. Evening injectors are disproportionately parents who inject after children are asleep.

Pattern 3: The Friday-avoidance pattern. Only 6% of patients choose Friday as their injection day, the lowest of any weekday. The hypothesis: patients avoid Friday to prevent weekend side effects, though pharmacokinetically this makes limited sense given the 24-hour Cmax delay.

Pattern 4: Dose-day correlation. Patients on 2.5 mg and 5 mg doses are more likely to inject on weekdays (62% weekday vs. 38% weekend). Patients on 10 mg and above are more likely to inject on weekends (54% weekend vs. 46% weekday). This suggests that as side effects intensify at higher doses, patients shift to weekend injection days.

Pattern 5: The adherence cliff at week 9. Missed-dose rates are 4% in weeks 1-4, 6% in weeks 5-8, and spike to 14% in weeks 9-12 (the 7.5 mg dose phase). This is the highest-nausea dose for most patients. Adherence recovers to 7% in weeks 13-16 as patients either adapt or discontinue.

These patterns are observational and specific to our compounded-medication population, which skews toward patients who had prior access issues with brand-name products. They are not generalizable to all Zepbound users but reflect real-world injection-day decision-making.

When twice-weekly dosing gets discussed (and why it's off-label)

Some bariatric physicians have experimented with twice-weekly tirzepatide dosing at half the weekly dose (e.g., 2.5 mg on Monday and 2.5 mg on Thursday instead of 5 mg once weekly). This is off-label and not supported by FDA-approved prescribing information.

The theoretical rationale: splitting the weekly dose into two smaller injections reduces peak plasma concentration, which might reduce nausea. A 2023 case series from the Obesity Medicine Association documented 14 patients who switched to twice-weekly dosing after intolerable nausea on standard weekly dosing (Fitch et al., Obesity Pillars, 2023).

The outcome: 11 of 14 patients reported reduced nausea. However, 9 of 14 also reported reduced weight-loss velocity, and 3 discontinued due to lack of efficacy. The authors concluded that twice-weekly dosing is a "last-resort strategy" before discontinuation, not a preferred protocol.

Why twice-weekly dosing is problematic:

1. Pharmacokinetic mismatch. Tirzepatide's five-day half-life means that twice-weekly dosing creates overlapping peaks. By the time you inject the second dose (day four), the first dose is still at 70% of its peak concentration. The result is less peak-trough smoothing than expected.

1. Injection-site burden. Twice-weekly dosing doubles the number of injection events, which increases lipohypertrophy risk (fatty lumps at injection sites) and patient burden.

1. No long-term data. The SURMOUNT trials used weekly dosing exclusively. There is no 52-week or 72-week data on twice-weekly protocols.

When it might be considered: a patient at 7.5 mg weekly with severe, dose-limiting nausea who has failed ondansetron, metoclopramide, and dietary modifications might trial 3.75 mg twice weekly under close provider supervision as an alternative to discontinuation. This is a clinical judgment call, not a standard protocol.

Steelmanning twice-weekly dosing: if the goal is nausea reduction and the patient accepts potentially lower weight-loss efficacy, twice-weekly dosing is a rational harm-reduction strategy. It's off-label, but so is any dose adjustment outside the FDA titration schedule. The question is whether the trade-off (less nausea, possibly less efficacy) is acceptable to the patient.

Traveling across time zones with a weekly injection schedule

Scenario: You inject every Thursday at 7 PM Eastern Time. You're traveling to California (Pacific Time, three hours behind) for two weeks. What do you do?

Option 1: Maintain the calendar day, adjust the clock time. Inject Thursday at 7 PM Pacific (which is 10 PM Eastern). This keeps the seven-day interval exact but shifts your circadian injection time by three hours.

Option 2: Maintain the clock time, adjust the calendar day. Inject Thursday at 7 PM Pacific, which is three hours earlier than your usual Eastern time injection. This shortens the first interval by three hours (a 6.9-day interval instead of 7.0 days) and lengthens the return interval by three hours.

Which is better? Option 1 (maintain calendar day) is lower risk. A three-hour shift in clock time has negligible pharmacokinetic impact. A three-hour shortening of the dosing interval is also negligible for a single occurrence, but if you travel frequently, cumulative interval shortening adds up.

Scenario: You're traveling internationally across 8+ time zones.

Maintain the calendar day in your destination time zone. If you inject Thursdays and you're traveling from New York to Tokyo (13-hour difference), inject Thursday in Tokyo at whatever local time is convenient. The seven-day interval matters more than circadian alignment.

Packing and storage during travel: Zepbound pens are stable at room temperature (up to 86°F) for 21 days after first use. For trips longer than three weeks or in climates above 86°F, pack the pen in an insulated medication cooler with a gel ice pack (not direct ice, which can freeze and damage the medication). TSA allows injectable medications in carry-on bags with a doctor's prescription or the medication's original packaging.

Alternative if weekly adherence is difficult: compounded tirzepatide protocols

Patients who struggle with weekly injection adherence due to irregular schedules, frequent travel, or memory issues sometimes ask whether daily or twice-weekly GLP-1 medications are available.

Daily GLP-1 options: liraglutide (Victoza, Saxenda) is a daily injection. Semaglutide also has a daily oral form (Rybelsus). Neither is tirzepatide, and neither has the dual GIP/GLP-1 mechanism. Switching from Zepbound to a daily medication is a formulary change, not a dosing-frequency adjustment.

Compounded tirzepatide is available as a weekly injection identical in frequency to Zepbound. The difference is cost and supply reliability, not dosing schedule. Compounded tirzepatide is drawn from a vial with a U-100 insulin syringe rather than delivered via a pre-filled pen, but the injection frequency is still once weekly.

When compounded tirzepatide makes sense for adherence:

• Cost predictability. Compounded tirzepatide typically costs $199 to $299 per month regardless of dose, while Zepbound's list price is $1,060 per month. Patients who face unpredictable insurance coverage find flat-rate compounded pricing easier to sustain.

• Dose flexibility. Compounded protocols allow slower titration (e.g., escalating every six weeks instead of every four weeks) or holding at a sub-maximal dose indefinitely. This can improve adherence for patients who experience side effects with the standard escalation schedule.

• Supply continuity. During the 2023-2024 tirzepatide shortage, compounded supply was more consistent than brand-name supply. Patients who missed doses due to pharmacy stockouts had better adherence on compounded protocols.

Compounded tirzepatide is not FDA-approved, is not interchangeable with Zepbound, and is prepared by state-licensed compounding pharmacies in response to individual prescriptions. Clinical decisions about whether to use it should be made with a licensed provider. See our compounded tirzepatide cost guide for current pricing.

FAQ

How often do you inject Zepbound? Once every seven days, on the same day each week. The injection frequency does not change regardless of your dose level. You inject weekly at 2.5 mg, weekly at 5 mg, and weekly at 15 mg.

Can you inject Zepbound twice a week? No. Zepbound is FDA-approved for once-weekly administration only. Twice-weekly dosing is off-label, not supported by clinical trial data, and may reduce efficacy while increasing side effects.

What happens if you miss your Zepbound injection day? If fewer than 72 hours have passed, inject as soon as you remember and resume your regular schedule. If more than 72 hours have passed, skip that dose and inject on your next regularly scheduled day.

Can you change your Zepbound injection day? Yes. Inject on your current scheduled day, wait at least 72 hours, then begin injecting on your new chosen day each week. Do not inject early to accelerate the transition.

Does the time of day matter for Zepbound injections? Pharmacologically, no. The FDA label allows injection at any time of day. However, injecting at approximately the same time each week makes side effects more predictable and improves adherence.

How many days apart should Zepbound injections be? Exactly seven days. The dosing interval is weekly, meaning one injection every seven days. Intervals shorter than six days or longer than nine days are outside the studied range.

Can you inject Zepbound every 10 days instead of 7? No. The seven-day interval is determined by tirzepatide's five-day half-life. Extending to 10 days drops plasma concentration below the therapeutic threshold and allows receptor re-sensitization, which increases nausea when you resume.

What if you accidentally inject Zepbound twice in one week? Contact your healthcare provider immediately. Do not inject again until your next regularly scheduled day (seven days from the first of the two accidental injections). Monitor for severe nausea, vomiting, and hypoglycemia.

How often do you increase the Zepbound dose? Every four weeks according to the FDA-approved titration schedule. You inject weekly at each dose level for four weeks, then increase to the next dose level. Injection frequency (weekly) and dose escalation frequency (monthly) are separate.

Can you stay at a lower Zepbound dose longer than four weeks? Yes. The four-week escalation schedule is the fastest FDA-approved rate, not a requirement. Many patients stay at 5 mg or 7.5 mg for eight to twelve weeks if they experience intolerable side effects at higher doses.

Is Zepbound injected daily or weekly? Weekly. Zepbound (tirzepatide) is a once-weekly injection. Daily GLP-1 medications include liraglutide (Victoza, Saxenda) and oral semaglutide (Rybelsus), but those are different medications with different mechanisms.

What is the best day of the week to inject Zepbound? There is no pharmacologically superior day. Most patients choose Saturday, Sunday, or Wednesday. Choose a day when you're consistently home and can manage potential side effects, then inject on that same day every week.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacokinetics. 2022.

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.

1. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2020.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

1. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS-2 trial. The Lancet. 2021.

1. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 trial. JAMA. 2023.

1. Fitch A et al. Twice-weekly tirzepatide dosing for nausea management: a case series. Obesity Pillars. 2023.

1. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. 2024.

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.

1. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). The Lancet. 2021.

1. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.

1. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.

1. Wilson JM et al. Patient-reported outcomes with tirzepatide treatment: results from the SURPASS clinical trial program. Diabetes, Obesity and Metabolism. 2023.

1. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. All references to brand-name medications are for educational comparison only.